Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Opiates, prolactin, and the dopamine receptor.

G Tolis, R Dent, H Guyda

    The Journal of Clinical Endocrinology and Metabolism
    |July 1, 1978
    PubMed
    Summary

    Opiates like morphine and methadone increase prolactin (PRL) levels by blocking dopamine receptors. Dopamine agonists prevent this effect, while serotonin antagonists do not, suggesting a dopamine-mediated mechanism for opiate-induced hyperprolactinemia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A drug-resistant TB cluster in a refugee family with Mendelian susceptibility to mycobacterial disease (MSDM).

    IJTLD open·2026
    Same author

    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Advancing breast cancer research through real-world data from the Singapore Joint Breast Cancer Registry.

    ESMO real world data and digital oncology·2026
    Same author

    Investigation of the distribution of laser-induced damage precursors in etched grating sidewalls fabricated using inductively coupled plasma reactive-ion etching.

    Optics express·2025

    Area of Science:

    • Neuroendocrinology
    • Pharmacology

    Background:

    • Dopamine is a key regulator of prolactin (PRL) secretion from the pituitary gland.
    • Opiates are known to affect neuroendocrine functions, but the precise mechanism of their effect on PRL is not fully understood.

    Purpose of the Study:

    • To investigate the role of dopamine receptors in mediating the prolactin-elevating effects of opiates.
    • To determine if opiate-induced hyperprolactinemia is dependent on dopamine receptor blockade.

    Main Methods:

    • Administration of dopamine antagonists (chlorpromazine) and opiates (morphine, methadone) to assess serum PRL levels.
    • Pre-treatment with dopamine receptor agonists (apomorphine, levodopa, bromocriptine) to evaluate their effect on opiate-induced PRL rise.
    • Administration of a serotonin antagonist (cyproheptadine) as a control.

    Main Results:

    • Chlorpromazine, morphine, and methadone significantly increased serum PRL levels within 90-150 minutes.
    • Prior administration of dopamine agonists completely blocked the PRL-elevating effect of opiates.
    • Cyproheptadine did not affect the opiate-induced increase in PRL.

    Conclusions:

    • Opiates induce hyperprolactinemia in humans primarily through the blockade of dopamine receptors.
    • The findings support a critical role for dopaminergic pathways in regulating PRL secretion and mediating the effects of certain drugs.

    Related Experiment Videos